2020
DOI: 10.1111/bph.15011
|View full text |Cite
|
Sign up to set email alerts
|

Old dog, new trick: Trivalent arsenic as an immunomodulatory drug

Abstract: Trivalent arsenic (As(III)) is recently found to be an immunomodulatory agent. As (III) has therapeutic potential in several autoimmune and inflammatory diseases in vivo.In vitro, it selectively induces apoptosis of immune cells due to different sensitivity. At a non-toxic level, As(III) shows its multifaceted nature by inducing either pro-or anti-inflammatory functions of immune subsets. These effects are exerted by either As(III)-protein interactions or as a consequence of As(III)-induced homeostasis imba… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
8
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 18 publications
(9 citation statements)
references
References 131 publications
0
8
0
Order By: Relevance
“…Arsenic trioxide (As 2 O 3 ), a well‐established drug for acute promyelocytic leukaemia, was observed to have therapeutic potential in pre‐clinical mouse models of SLE, 155 SSc 156 and sclerodermatous GVHD, 157 with unknown mechanism 158 . Our group has recently offered a potential explanation by demonstrating that clinically relevant concentrations of As 2 O 3 preferentially block IFN‐α secretion from pDCs through IRF7 inhibition and also impair the capacity of pDCs to induce T‐/B‐cell responses 159 .…”
Section: Targeting Pdc Functions In Autoimmunity and Alloreactivitymentioning
confidence: 99%
“…Arsenic trioxide (As 2 O 3 ), a well‐established drug for acute promyelocytic leukaemia, was observed to have therapeutic potential in pre‐clinical mouse models of SLE, 155 SSc 156 and sclerodermatous GVHD, 157 with unknown mechanism 158 . Our group has recently offered a potential explanation by demonstrating that clinically relevant concentrations of As 2 O 3 preferentially block IFN‐α secretion from pDCs through IRF7 inhibition and also impair the capacity of pDCs to induce T‐/B‐cell responses 159 .…”
Section: Targeting Pdc Functions In Autoimmunity and Alloreactivitymentioning
confidence: 99%
“…ATO may also induce the expression of molecules on the surface of tumor cells that make them more visible to the immune system, leading to increased recognition and elimination of the tumor cells by immune cells. 77 Based on the above results, we can speculate that MSN and ATO can synergistically activate anti-tumor immune responses. The possible mechanism is that, on one hand, MSN acting as an immune stimulator with certain immune activity can also create a chronic, sustained inflammatory response.…”
Section: Paper Biomaterials Sciencementioning
confidence: 68%
“…ATO may also induce the expression of molecules on the surface of tumor cells that make them more visible to the immune system, leading to increased recognition and elimination of the tumor cells by immune cells. 77…”
Section: Resultsmentioning
confidence: 99%
“…The toxicity of arsenic depends on its chemical form, with arsenic pentavalent (As(V)) being highly toxic and trivalent arsenic (As (III)) demonstrating therapeutic potential for autoimmune and inflammatory diseases (Kumar et al 17 ). Over 200 million people in countries such as India, Bangladesh, Argentina, China, Ghana, the USA, and Vietnam face a high risk of arsenic exposure 24 , 25 .…”
Section: Introductionmentioning
confidence: 99%